JMJorge Melones-Herrero

Jorge Melones-Herrero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jorge Melones-Herrero has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Adoracion Gomez Quiroga

    Department of Inorganic Chemistry, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain

    5 shared publications
  • Isabel Sánchez-Pérez

    Department of Biochemistry, School of Medicine, UAM, Madrid 28029, Spain; Instituto de Investigaciones Biomédicas "Sols-Morreale" (IIBM), CSIC-UAM, Madrid 28029, Spain; Biomarkers and Personalized Approach to Cancer (BioPAC) Group. Area 3 Cancer -Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid 28034, Spain; Unidad Asociada de Biomedicina UCLM-CSIC, Madrid 28029, Spain; Centro de Investigación Biomédica en Red, Área Rare Diseases, CIBERER, ISCIII, Madrid 28029, Spain

    4 shared publications
  • Carmela Calés

    Department of Biochemistry, Instituto de Investigaciones Biomédicas ‘A. Sols’, Universidad Autónoma‐CSIC, Madrid, Spain

    3 shared publications
  • Ana Isabel Matesanz

    Department of Inorganic Chemistry, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain

    2 shared publications
  • J. Bargiela-Iparraguirre

    Dpto. de Bioquímica. Fac. Medicina, UAM, Madrid 28029, Spain

    2 shared publications
  • N. Pajuelo-Lozano

    Dpto. de Bioquímica. Fac. Medicina, UAM, Madrid 28029, Spain

    2 shared publications

Latest Publications

  • Open Access

    Trans-[Pt(amine)Cl2(PPh3)] Complexes Target Mitochondria and Endoplasmic Reticulum in Gastric Cancer Cells

    by Jorge Melones-Herrero, Patricia Delgado-Aliseda, Sofía Figueiras, Javier Velázquez-Gutiérrez, Adoración Gomez Quiroga, Carmela Calés, Isabel Sánchez-Pérez

    Gastric cancer prognosis is still notably poor despite efforts made to improve diagnosis and treatment of the disease. Chemotherapy based on platinum agents is generally used, regardless of the fact that drug toxicity leads to limited clinical efficacy. In order to overcome these problems, our group has been working on the synthesis and study of trans platinum (II) complexes. Here, we explore the potential use of two phosphine-based agents with the general formula trans-[Pt(amine)Cl2(PPh3)], called P1 and P2 (with dimethylamine or isopropylamine, respectively). A cytotoxicity analysis showed that P1 and especially P2 decrease cell viability. Specifically, P2 exhibits higher activity than cisplatin in gastric cancer cells while its toxicity in healthy cells is slightly lower. Both complexes generate Reactive Oxygen Species, produce DNA damage and mitochondrial membrane depolarization, and finally lead to induced apoptosis. Thus, an intrinsic apoptotic pathway emerges as the main type of cell death through the activation of BAX/BAK and BIM and the degradation of MCL1. Additionally, we demonstrate here that P2 produces endoplasmic reticulum stress and activates the Unfolded Protein Response, which also relates to the impairment observed in autophagy markers such as p62 and LC3. Although further studies in other biological models are needed, these results report the biomolecular mechanism of action of these Pt(II)-phosphine prototypes, thus highlighting their potential as novel and effective therapies.


  • Open Access

    Platinum iodido drugs show potential anti-tumor activity, affecting cancer cell metabolism and inducing ROS and senescence in gastrointestinal cancer cells

    by Jorge Melones-Herrero, Sonia Alcalá, Laura Ruiz-Cañas, Carlos Benítez-Buelga, Sandra Batres-Ramos, Carmela Calés, Oscar Lorenzo, Rosario Perona, Adoración G. Quiroga, Bruno Sainz, et al.

    Cisplatin-based chemotherapy has associated clinical disadvantages, such as high toxicity and resistance. Thus, the development of new antitumor metallodrugs able to overcome different clinical barriers is a public healthcare priority. Here, we studied the mechanism of action of the isomers trans and cis-[PtI2(isopropylamine)2] (I5 and I6, respectively) against gastrointestinal cancer cells. We demonstrate that I5 and I6 modulate mitochondrial metabolism, decreasing OXPHOS activity and negatively affecting ATP-linked oxygen consumption rate. Consequently, I5 and I6 generated Reactive Oxygen Species (ROS), provoking oxidative damage and eventually the induction of senescence. Thus, herein we propose a loop with three interconnected processes modulated by these iodido agents: (i) mitochondrial dysfunction and metabolic disruptions; (ii) ROS generation and oxidative damage; and (iii) cellular senescence. Functionally, I5 reduces cancer cell clonogenicity and tumor growth in a pancreatic xenograft model without systemic toxicity, highlighting a potential anticancer complex that warrants additional pre-clinical studies.


  • Open Access

    Regulatory effects of miR-19a on MAD2 expression and tumorigenesis in gastric cancer

    by J. Bargiela-Iparraguirre, J.M. Herrero, N. Pajuelo-Lozano, M. Perez, R. Perona, A.G. Quiroga, C. Calés, I. Sanchez-Perez


  • Open Access

    Regulatory effects of miRNA-19a on MAD2 expression and tumorigenesis in gastric cancer

    by J. Bargiela-Iparraguirre, J.M. Herrero, N. Pajuelo-Lozano, M. Perez, C. Cales, R. Perona, A.G. Quiroga, I. Sanchez-Perez

    MAD2 is a key mitotic checkpoint protein that when overexpressed provokes chromosomal instability in gastric cancer. In this work, we used in silico analysis in combination with in vitro studies and clinical data to explore if miRNAs can regulate MAD2 at post-transcriptional level. By in silico analysis, we discriminate the expression of miRNAs between tumor and normal tissue, finding miR-19a and miR-203 targeted to 3’UTR MAD2L1 . Luciferase Assays proved that those miR’s are specific to MAD2L1 in human cells. RT-qPCR showed an inverse correlation between the expression miRNA19 and 203 and MAD2L1 in a panel of gastric cancer cell lines and in a pilot series of patients’ study. The miR-19a expression reduces the migration ability of AGS cells and invasion in MKN45 cells. Furthermore, the expression of the miRNA in combination with mitotic checkpoint drugs increase apoptosis. Finally, the TCGA analysis showed that Gastric Cancer patients with overexpression of MAD2, showed higher overall survival when miR-19a was overexpressed. Together, our results defined miR-19a as a critical regulator of MAD2 protein in Gastric Cancer and could potentially be used as a prognostic biomarker in clinical use.

  • Two Different Thiosemicarbazone Tauto‐Conformers Coordinate to Palladium (II). Stability and Biological Studies of the Final Complexes

    by David Fabra, Ana I. Matesanz, Jorge M. Herrero, Cristina Alvarez, Lucia M. Balsa, Ignacio E. Leon, Adoracion Gomez Quiroga

    Thiosemicarbazone moiety is a valuable scaffold for the synthesis of metallic complexes with anticancer purposes, when bearing N‐heterocyclic the final compounds possess diverse biological activities. Using thiazole as bioisosteres, the resulting thiosemicarbazones can afford synthetic drugs with a variety of pharmacological effects. Trying to elucidate, if metal complexes from α‐N‐heterocyclic thiosemicarbazones can achieve more selectivity versus special tumor lines, we have developed new metal complexes with 1H imidazole‐4‐carboxaldehyde 4 N‐p‐tolyl‐ and 4 N‐phenylthiosemicarbazone (HL1and HL2respectively). The solution studies of these ligands showed a tautomeric equilibria in solution and their reaction with Li2PdCl4proved the stability of both forms affording two mononuclear Pd(II) complexes. Both tautomeric forms are clearly coordinated to palladium center acting as two different bidentate ligands. Palladium complexes’ stability in biological buffers was investigated to stablish the optimal conditions for the evaluation of cytotoxicity, that on the triple negative adenocarcinoma cell line showed IC50values in the low micromolar range. Complexes were also studied with CT DNA (UV‐Visible spectroscopy and viscosity) and with the pBR322 plasmid supercoiled models, indicating non covalent interaction.


  • Chemical and Biological Evaluation of Thiosemicarbazone-Bearing Heterocyclic Metal Complexes

    by Ana I. Matesanz, Jorge M. Herrero, Adoración G. Quiroga

    Thiosemicarbazones (TSCNs) constitute a broad family of compounds (R1R2C=N-NH-C(S)- NR3R4), particularly attractive because many of them display some biological activity against a wide range of microorganisms and cancer cells. Their activity can be related to their electronic and structural properties, which offer a rich set of donor atoms for metal coordination and a high electronic delocalization providing different binding modes for biomolecules. Heterocycles such as pyrrole, imidazole and triazole are present in biological molecules such as Vitamine B12 and amino acids and could potentially target multiple biological processes. Considering this, we have explored the chemistry and biological properties of thiosemicarbazones series and their complexes bearing heterocycles such as pyrrole, imidazole, thiazole and triazole. We focus at the chemistry and cytotoxicity of those derivatives to find out the structure activity relationships, and particularly we analyzed those examples with the TSCN units in which the mechanism of action information has been profoundly studied and pathways determined, to promote future studies for heterocycle derivatives.